

=> e bisoprolol

E1	1	BISOPP/BI
E2	1	BISOPROL/BI
E3	882 -->	BISOPROLOL/BI
E4	2	BISOPROLOLFUMARATE/BI
E5	1	BISOPROLOLIS/BI
E6	1	BISOPROPOLOL/BI
E7	1	BISOPT/BI
E8	1	BISOR/BI
E9	2	BISORANJIDIOL/BI
E10	2	BISORBATE/BI
E11	1	BISORBENT/BI
E12	4	BISORBIBETANONE/BI

=> s e3

L1 882 BISOPROLOL/BI

=> s l1 and transdermal\

14075 TRANSDERMAL
6 TRANSDERMALS
14076 TRANSDERMAL\
(TRANSDERMAL OR TRANSDERMALS)

L2 17 L1 AND TRANSDERMAL\

=> s l1 and transdermal

14075 TRANSDERMAL
6 TRANSDERMALS
14076 TRANSDERMAL
(TRANSDERMAL OR TRANSDERMALS)

L3 17 L1 AND TRANSDERMAL

=> d 1-3 ibib abs

L3 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:672883 CAPLUS <<LOGINID::20070710>>

DOCUMENT NUMBER: 147:58405

TITLE: Adhesive patch preparation

INVENTOR(S): Iwao, Yoshihiro; Ookubo, Katsuyuki; Okada, Katsuhiko

PATENT ASSIGNEE(S): Nitto Denko Corporation, Japan

SOURCE: PCT Int. Appl., 34pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007069662	A1	20070621	WO 2006-JP324875	20061213
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,			

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

JP 2005-358469

A 20051213

JP 2006-328952

A 20061206

AB Disclosed is an adhesive preparation of the invention comprises a support and an adhesive layer laminated on one surface thereof. The adhesive layer is characterized by containing a branched monohydric alc. having 12 to 28 carbon atoms, a drug which is in a liquid state at or near room temperature (with the proviso that a bisoprolol free base is excluded) and a polyisobutylene adhesive. This can specifically increase the compatibility between the polyisobutylene adhesive and the drug. As a result, the blending amount of the drug can be increased, the bleed of drug from the adhesive layer can be suppressed, and further, a sufficient adhesive property can be obtained in the practical point of view. For example, an adhesive layer composition containing emedastine 7.5, 2-octyl-1-dodecanol 15, an adhesive composition containing polyisobutylene (Oppanol

B200)/polyisobutylene (HIMOL6H)/tackifier (Arkon P140) at 34/26/40 77.5 % was formulated, and applied between a PET liner and a PET base film to obtain an adhesive patch of the present invention.

REFERENCE COUNT:

40

THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:671886 CAPLUS <<LOGINID::20070710>>

DOCUMENT NUMBER: 147:58403

TITLE: Bisoprolol-containing adhesive patch

INVENTOR(S): Iwao, Yoshihiro; Ookubo, Katsuyuki; Okada, Katsuhiko;
Minami, Kunihiro; Yuasa, Shuichiro

PATENT ASSIGNEE(S): Nitto Denko Corporation, Japan; Toa Eiyo Ltd.

SOURCE: PCT Int. Appl., 28pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007069661	A1	20070621	WO 2006-JP324874	20061213
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.:

JP 2005-358470

A 20051213

JP 2006-328922

A 20061206

AB Disclosed is a bisoprolol-containing adhesive patch which comprises a support and an adhesive layer superposed on one side thereof. The adhesive layer is characterized by comprising a branched C12-28 monohydric alc., a free bisoprolol base, and a polyisobutylene-based pressure-sensitive adhesive. In this constitution, the compatibility

between the polyisobutylene-based pressure-sensitive adhesive and the free bisoprolol base can be specifically heightened. As a result, it is possible to incorporate the free bisoprolol base in a large amount. The pressure-sensitive adhesive layer can be inhibited from suffering the bleeding of the free bisoprolol base and have practically sufficient pressure-sensitive adhesive properties. For example, an adhesive layer composition containing free bisoprolol base 2, 2-octyl-1-dodecanol 5, an adhesive composition containing polyisobutylene

(Oppanol

B200)/polyisobutylene (HIMOL6H)/a tackifier (Arkon P140) at 34/26/40, 83, and iso-Pr myristate 10 % was formulated, and applied on between a polyethylene terephthalate e liner and a polyethylene terephthalate base film to obtain an adhesive patch of the present invention.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:644233 CAPLUS <<LOGINID::20070710>>

DOCUMENT NUMBER: 147:39213

TITLE: Transdermal patch containing isosorbide dinitrate and bisoprolol

INVENTOR(S): Wang, Shuming; Wang, Li; Fan, Xiaoling; Xue, Huiyong; Zhang, Shuang; Zhang, Enhong; Zhong, Xuying; Lu, Yucheng; Li, Chun; Song, Li

PATENT ASSIGNEE(S): Beijing Kangbeide Pharmaceutical Technology Development Co., Ltd., Peop. Rep. China

SOURCE: PCT Int. Appl., 43pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007065303	A1	20070614	WO 2005-CN2136	20051209
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: WO 2005-CN2136 20051209

AB A transdermal patch in the form of composite layer comprising a packing layer, a drug storing layer containing active substance and pharmaceutical adjuvants, and a protecting layer located on the top of the drug storing layer. This transdermal patch is best characterized by the fact that the said drug storing layer contains isosorbide dinitrate and bisoprolol as the active components in a ratio of 1:3 to 3:1 by weight. The animal expts. show that the patch can decrease the escalation of electrocardiogram T wave, the rising of Serum Cardioenzyme and the extension of heart infarction by coronary ligation performed on animals. and this confirms that this patch displays a

significant synergistic effect on the treatment of cardiovascular diseases, and it can also serve as a good prevention and treatment against the occurrence of a variety of heart diseases: Besides, the hypotensive efficacy observed in animal expts. better than those when administering each active drugs individually, while arrhythmia which often occurs when applying either of them alone is not aggravated.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s 13 and PY<2003

22885814 PY<2003

L4 7 L3 AND PY<2003

=> d 1-3 ibib abs

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:833515 CAPLUS <<LOGINID::20070710>>

DOCUMENT NUMBER: 137:333176

TITLE: As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation

INVENTOR(S): Tam, Peter; Gesundheit, Neil; Wilson, Leland F.

PATENT ASSIGNEE(S): Vivus, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 15 pp., Cont.-in-part of U.S. Ser. No. 721,412.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002161016	A1	20021031	US 2001-996407	20011121 <--
US 6946141	B2	20050920		
US 6495154	B1	20021217	US 2000-721412	20001121 <--

PRIORITY APPLN. INFO.: US 2000-721412 A2 20001121

AB A method is provided for treatment of premature ejaculation by administration of an antidepressant drug selected from tricyclic antidepressants, tetracyclic antidepressants, MAO inhibitors, azaspirone antidepressants, and atypical non-SRI antidepressants. In a preferred embodiment, administration is on an "as-needed" basis, i.e., the drug is administered immediately or at most several hours prior to sexual activity. Pharmaceutical formulations and packaged kits are also provided.

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:408516 CAPLUS <<LOGINID::20070710>>

DOCUMENT NUMBER: 136:406871

TITLE: As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation

INVENTOR(S): Tam, Peter; Gesundheit, Neil; Wilson, Leland F.

PATENT ASSIGNEE(S): Vivus, Inc., USA

SOURCE: PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002041883	A2	20020530	WO 2001-US44065	20011121 <--
WO 2002041883	A3	20031218		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 6495154	B1	20021217	US 2000-721412	20001121 <--
CA 2429516	A1	20020530	CA 2001-2429516	20011121 <--
AU 2002028643	A5	20020603	AU 2002-28643	20011121 <--
EP 1389115	A2	20040218	EP 2001-989759	20011121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004536024	T	20041202	JP 2002-544062	20011121
PRIORITY APPLN. INFO.:				
			US 2000-721412	A 20001121
			WO 2001-US44065	W 20011121

AB A method is provided for treatment of premature ejaculation by administration of an antidepressant drug selected from tricyclic antidepressants, tetracyclic antidepressants, MAO inhibitors, azaspirone antidepressants, and atypical non-SRI antidepressants. In a preferred embodiment, administration is on an "as-needed" basis, i.e., the drug is administered immediately or at most several hours prior to sexual activity. Pharmaceutical formulations and packaged kits are also provided. An effervescent tablet contained clomipramine hydrochloride 300, sodium bicarbonate 1985, and citric acid 1000 mg. Efficacy of the compns. were tested in volunteers.

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:754414 CAPLUS <<LOGINID::20070710>>

DOCUMENT NUMBER: 133:325631

TITLE: Stereospecific delivery of a drug using electrotransport

INVENTOR(S): Gupta, Suneel K.; Sathyan, Gayatri; Padmanabhan, Rama

PATENT ASSIGNEE(S): ALZA Corporation, USA

SOURCE: U.S., 22 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6136327	A	20001024	US 1997-982245	19971201 <--
JP 2001524364	T	20011204	JP 2000-522969	19981130 <--
PRIORITY APPLN. INFO.:				
			US 1997-982245	A 19971201
			WO 1998-US25387	W 19981130

AB Preferential delivery via electrotransport of a preferred isomeric form of a pharmaceutically active chiral compound from a mixture of the isomeric forms

of said compound is provided. A method of decreasing the delivery via electrotransport of a less preferred isomer of a drug is also provided. Following electrotransport administration of ketorolac, the mean amount of R isomer absorbed was lower than that of the S isomer.

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 4-7 ibib abs

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:123954 CAPLUS <<LOGINID::20070710>>

DOCUMENT NUMBER: 132:284068

TITLE: A comparative in vitro study of percutaneous penetration of β -blockers in human skin

AUTHOR(S): Modamio, P.; Lastra, C. F.; Marino, E. L.

CORPORATE SOURCE: Faculty of Pharmacy, Clinical Pharmacy and Pharmacotherapy Unit, Department of Pharmacy and Pharmaceutical Technology, University of Barcelona, Barcelona, 08028, Spain

SOURCE: International Journal of Pharmaceutics (2000), 194(2), 249-259

CODEN: IJPHDE; ISSN: 0378-5173

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In vitro diffusion expts. with propranolol, oxprenolol, metoprolol and atenolol were carried out using excised human abdominal skin. The main permeation parameters (permeability coefficient, flow and lag time) were calculated

and compared as measurement of intrinsic permeability across human skin. A long lag time and a low steady-state flow were found for all drugs assayed. Skin permeability predicted at steady state did not reach therapeutic concns., which indicated the need for appropriate chemical penetration enhancers or vehicles to overcome limiting factors. The results, including those of celiprolol and bisoprolol reported previously, correlated with physicochem. properties, especially with lipophilicity, one of the main factors in drug permeability prediction through human skin.

REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:623630 CAPLUS <<LOGINID::20070710>>

DOCUMENT NUMBER: 130:57078

TITLE: Transdermal absorption of celiprolol and bisoprolol in human skin in vitro

AUTHOR(S): Modamio, P.; Lastra, C. F.; Marino, E. L.

CORPORATE SOURCE: Faculty of Pharmacy, Department of Pharmacy and Pharmaceutical Technology, Clinical Pharmacy and Pharmacotherapy Unit, University of Barcelona, Barcelona, 08028, Spain

SOURCE: International Journal of Pharmaceutics (1998), 173(1,2), 141-148

CODEN: IJPHDE; ISSN: 0378-5173

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Two β -blockers, celiprolol and bisoprolol, which have a

priori interesting properties to be considered in the search of a possible candidate for a transdermal therapeutic system (TTS) were assayed. In vitro permeation studies were conducted at 32° across human abdominal skin. Franz glass diffusion cells were used in the static mode. The amts. of drug permeated from receptor solution at predetd. times were analyzed by reversed-phase HPLC with UV detection. From the penetration profiles obtained for each drug, the main permeation parameters, permeability coefficient (Kp), flow (J) and lag time (Tlag) were estimated as a measure of the intrinsic permeability across human skin. Mean Kp value was higher for celiprolol (0.59 cm h⁻¹) than bisoprolol (0.27+10⁻³ cm h⁻¹), although both were very low. Mean J value was also higher for celiprolol (2.72 µg h⁻¹ cm⁻²) than bisoprolol (1.19 µg h⁻¹ cm⁻²). Mean Tlag value was 20.43 h for celiprolol and 32.13 h for bisoprolol. Both provide plasma concns. at steady state that would be far from their therapeutic concentration. The results indicate the need for appropriate enhancers to improve their diffusion across human skin.

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:621110 CAPLUS <<LOGINID::20070710>>

DOCUMENT NUMBER: 129:239887

TITLE: Use of antiarrhythmic benzofuran derivatives for reducing death rate after myocardial infarction

INVENTOR(S): Frangin, Gerald; Malik, Marek

PATENT ASSIGNEE(S): Sanofi, Fr.

SOURCE: PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9840067	A1	19980917	WO 1998-FR453	19980306 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
FR 2760364	A1	19980911	FR 1997-2807	19970310 <--
AU 9868400	A	19980929	AU 1998-68400	19980306 <--
PRIORITY APPLN. INFO.:			FR 1997-2807	A 19970310
			WO 1998-FR453	W 19980306

AB The invention concerns the use of benzofuran derivs. with antiarrhythmic activity, or one of the pharmaceutically acceptable salts thereof, as active principles for preparing pharmaceutical compns. to reduce global death rate among patients having, after myocardial infarction, a reduced left ventricular function and a depressed variability of cardiac rate, without cardiac dysrhythmia requiring an antiarrhythmic treatment.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:640537 CAPLUS <<LOGINID::20070710>>
 DOCUMENT NUMBER: 127:303335
 TITLE: Use of antiarrhythmic compounds for reducing
 post-infarction mortality
 INVENTOR(S): Frangin, Gerald; Munoz, Alain
 PATENT ASSIGNEE(S): Sanofi, Fr.
 SOURCE: PCT Int. Appl., 41 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9734597	A1	19970925	WO 1997-FR474	19970317 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU RW: GH, KE, LS, MW, SD, SZ, UG, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
FR 2746013	A1	19970919	FR 1996-3357	19960318 <--
FR 2746013	B1	19980529		
EP 796617	A1	19970924	EP 1997-400593	19970317 <--
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2249481	A1	19970925	CA 1997-2249481	19970317 <--
AU 9722962	A	19971010	AU 1997-22962	19970317 <--
AU 719358	B2	20000504		
CN 1213965	A	19990414	CN 1997-193158	19970317 <--
JP 11507063	T	19990622	JP 1997-533201	19970317 <--
JP 3253092	B2	20020204		
US 5985915	A	19991116	US 1997-819863	19970317 <--
NZ 331931	A	20000825	NZ 1997-331931	19970317 <--
HU 9902580	A2	20010528	HU 1999-2580	19970317 <--
ZA 9702340	A	19980918	ZA 1997-2340	19970318 <--
NO 9804299	A	19981117	NO 1998-4299	19980917 <--
PRIORITY APPLN. INFO.:			FR 1996-3357	A 19960318
			WO 1997-FR474	W 19970317

AB The use is disclosed of benzofuran derivs. having antiarrhythmic activity, particularly amiodarone or dronedarone, or a pharmaceutically acceptable salt thereof, for preparing pharmaceutical compns. capable of reducing cardiac-related mortality, particularly arrhythmia-related mortality and sudden death in patients who have a reduced left ventricular function following a myocardial infarction but do not have a disturbed cardiac rhythm requiring an antiarrhythmic treatment. Formulations are included, as are the results of a clin. study.